Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]-FBR
- Development stage
- Unknown
- Lead developer
- National Institutes of Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]-FBR (also known as [18F]PBR06) is a second-generation fluorine-18 labeled radiopharmaceutical that acts as a high-affinity ligand for the 18 kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR). TSPO is located on the outer mitochondrial membrane and is highly upregulated in activated microglia and macrophages during neuroinflammatory processes. [18F]-FBR is utilized as a positron emission tomography (PET) imaging tracer to non-invasively detect, map, and quantify neuroinflammation and microglial activation in vivo. It has been investigated in clinical and preclinical studies for various central nervous system disorders, including multiple sclerosis, Alzheimer's disease, multiple system atrophy, epilepsy, and neurocysticercosis, as well as in oncology (glioma) and cardiovascular disease (atherosclerosis).
- Other names
- 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyanilineN-(2,5-dimethoxybenzyl)-2-[18F]fluoro-N-(2-phenoxyphenyl)acetamidePBR-06 F-18PBR06 F-18PBR 06 F-18[18F]PBR06
02
Targets
GABAA (Gamma-aminobutyric acid receptor)TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on [18F]-FBR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]-FBR.